DexCom, Inc. $DXCM Shares Purchased by Swedbank AB

Key Points

• Swedbank AB increased its ownership in DexCom, Inc. by 1.5%, bringing its total shares to 225,953 valued at approximately $15.43 million.
• Recent transactions show several institutional investors, including Brighton Jones LLC and Bank Pictet & Cie Europe AG, significantly increased their stakes in DexCom during the previous quarter.
• DexCom reported better-than-expected earnings with an EPS of $0.48, surpassing analysts' estimates and showing a year-over-year revenue growth of 15.2%.

Swedbank AB lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 1.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 225,953 shares of the medical device company's stock after purchasing an additional 3,328 shares during the period. Swedbank AB owned 0.06% of DexCom worth $15,430,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in the company. Horizon Investments LLC grew its position in DexCom by 2.2% during the first quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company's stock worth $383,000 after buying an additional 123 shares in the last quarter. Wedbush Securities Inc. lifted its stake in shares of DexCom by 1.2% in the 1st quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company's stock valued at $899,000 after acquiring an additional 157 shares during the last quarter. Argonautica Private Wealth Management Inc. lifted its stake in shares of DexCom by 3.2% in the 1st quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company's stock valued at $407,000 after acquiring an additional 182 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. lifted its stake in shares of DexCom by 3.2% in the 1st quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,019 shares of the medical device company's stock valued at $411,000 after acquiring an additional 187 shares during the last quarter. Finally, Integrated Wealth Concepts LLC raised its position in DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company's stock worth $227,000 after purchasing an additional 196 shares during the last quarter. Institutional investors own 97.75% of the company's stock.

DexCom Stock Up 1.3%

Shares of NASDAQ DXCM traded up $0.97 on Tuesday, reaching $76.55. 4,300,479 shares of the company's stock traded hands, compared to its average volume of 4,073,249. The business's 50 day simple moving average is $80.58 and its two-hundred day simple moving average is $78.47. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $93.25. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The company has a market cap of $30.02 billion, a price-to-earnings ratio of 53.16, a price-to-earnings-growth ratio of 1.58 and a beta of 1.48.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm's revenue was up 15.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Truist Financial assumed coverage on DexCom in a report on Monday, June 16th. They set a "buy" rating and a $102.00 price target for the company. William Blair upgraded DexCom to a "strong-buy" rating in a report on Thursday, July 31st. Raymond James Financial increased their price target on DexCom from $99.00 to $102.00 and gave the stock a "strong-buy" rating in a report on Thursday, July 31st. Argus initiated coverage on DexCom in a report on Thursday, August 21st. They set a "buy" rating and a $100.00 price target for the company. Finally, Oppenheimer downgraded DexCom from an "outperform" rating to a "market perform" rating in a research note on Monday, September 8th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, DexCom presently has an average rating of "Moderate Buy" and an average target price of $99.89.

Insider Buying and Selling at DexCom

In related news, EVP Michael Jon Brown sold 500 shares of the business's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the transaction, the executive vice president owned 94,102 shares in the company, valued at $7,555,449.58. The trade was a 0.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Mark G. Foletta sold 2,750 shares of the company's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $81.06, for a total transaction of $222,915.00. Following the transaction, the director owned 51,121 shares in the company, valued at $4,143,868.26. The trade was a 5.10% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 8,315 shares of company stock valued at $689,431. Corporate insiders own 0.32% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.